MedTech company secures Chinese distribution deal
Regenerative medical device company, Tissue Regenix, has signed an exclusive distribution agreement with Kingsung Medical Group, a Hong Kong-based medical enterprise, for the distribution of OrthoPure® XT in China.
This product uses Tissue Regenix’s patented dCELL® technology and is the only available, non-human biologic graft indicated for certain ligament reconstruction procedures.
It can be used for the revision of anterior cruciate ligament reconstruction procedures and reconstruction of other knee ligaments, including multi-ligament and primary procedures when an autograft is not an option.
The initial agreement is for six years and requires Kingsung Medical to purchase a minimum unit volume each year to maintain its exclusive status.
Daniel Lee, CEO of Tissue Regenix, said: “In the last year, we secured significant geographical partnerships in Germany and Italy and now in China for OrthoPure® XT.
“The market for anterior cruciate ligament (ACL) reconstruction in China is estimated to be in the range of 200,000-250,000 procedures per year, and this market needs additional graft options.
“We are happy to be partnering with Kingsung Medical and hope this will be the start of a strong relationship as we continue to expand our geographical footprint into new territories.”
Echo Liu, chairman and president of Kingsung Medical Group, added: “Adhering to the development philosophy of ‘professional and innovation-oriented’, Kingsung Medical has always been committed to providing surgeons and patients with the world’s leading new technologies and products with unique clinical value.
“With the rapid development of sports medicine in China, we are pleased to introduce OrthoPure® XT to the Chinese market.
“We will accelerate the registration and launch of OrthoPure® XT in China and promote its emergence as a new option to allow patients with knee ligament injuries to achieve excellent treatment results earlier.
“We firmly believe that this new technology will inject impetus into the development of China’s healthcare industry and benefit more patients.”
